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Conclusions: In the described typical population of patients with HCM receiving ICDs: (1) 
There is a low incidence of appropriate shock therapy during an intermediate follow-up 
period, occurring in only 1 pt (5%). To date, no pts presenting with syncope or presyn- 
cope, without documented prior clinical arrhythmias, have experienced sustained v-r at 
follow-up, suggesting a possible non-arrhythmic mechanism for syncope. (2) In contrast, 
29% of pts expedanced inappropriate shocks, most often due to SVAs. Careful attention 
to device programming, or perhaps implantation of dual chamber devices with utilization 
of detection enhancements, may help reduce inappropriate therapy. 
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829-1 The Relation of Magnesium Treatment and Blood 
Magnesium Levels With Development of Atr ia l  
F ibr i l la t ion After Coronary Artery Bypass Surgery 
Sinan Daodelen. Fevzi Toraman, Hasan Karabulut, Cem Alhan, Kosuyolu Heart and 
Research Hospital, Istanbul, Turkey, Acibadem Hospital, Istanbul, Turke~ 
It is well known that magnesium (Mg) treatment has beneficial effects on both ventricular 
and atrial arrhythmia. But there is no previous data concerning the relationship between 
blood Mg cutoff point level and atrial fibrillation (AF) developing after coronary bypass 
surgery, The aim of our study was to investigate the relationship between blood Mg lev- 
els and development of post bypass surgery AF and the effect of Mg treatment on AlE 
Method: A hundred and forty eight consecutive patients undergoing coronary artery 
bypass surgery (33F,115M; mean age 62.1±7.0 years) were enrolled to the study as two 
subgroups. Group A consisted of 93 pts to whom 1.5 g/day MgSO4 infusion were applied 
the day before surgery, just after operation, and 4 days following surgery, and Group B 
consisted of 55 control pts. Preoperative and postoperative 12 leads ECG recordings 
and blood Mg levels were analyzed daily for four days. Results: AF developed in 2 (2%) 
pts in group A and in 20 (36%) pts in group B (p<0.001). Baseline Mg level was similar in 
two groups. Fourth day Mg level was significantly higher in group A pts (2.21±0.23 vs 
1.9±0.14 mg/dl; p<0.001). When pts who developed AF and who did not were compared, 
baseline Mg level was similar. Fourth day Mg level was significantly lower in pts who 
developed AF after surgery (2.00±0.23 vs 2.15±0.26 mg/dl; p<0.001 ). When the relation- 
ship of Mg levels and AF development were investigated with ROC analysis, Mg cutoff 
point value was found to be 2.37 mg/dl, with very low sensitivity (18%) and specific- 
ity(12%). Conclusion: Mg treatment after coronary bypass surgery significantly reduces 
the risk of AlE The calculatsd cutoff point value of 2.37 mg/dl for Mg levels to impede AF 
is not predictive. 
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829-2 A Prospective and Randomized Study on the Effect of 
an Ang lo tens in  II Type  I Receptor Blocker I rbesartan in 
Maintaining Sinus Rhythm in Patients With Persistent 
Atr ia l  F ibr i l la t ion 
Antonio Hernandaz-Meddd. Jose G. Rebollo, Anibal Rodriguez, Manuel G. Bueno, Lucas 
Cano, Jose Manuel Cano, Gonzalo Pef~a, Gonzalo Pens, Driss Melehi, Detalina Savova, 
Asuncion Camino, Concepcion Moro, Ramon y Cajal, Madrid, Spain, Alcala University, 
Madrid, Spain. 
Background: the tissue angiotensin II has been recently implicated in atrial electrical 
remodelling, but there is no clinical human study at this point. The main objective of our 
study was to evaluate the effects of an antagonist of angiotensin II receptors on the acute 
efficacy of external electrical cardioversion and the early recurrences of atrial fibrillation, 
during the acute phase of electrical remodelling, to test the hypothesis that the combina- 
tion of angiotensin II antagonists Irbesartan plus amiodarone is more efficaccious in pre- 
venting recurrent atrial fibrillation than amiodarone alone. 
Methods: This is an interventional, prospective, randomized and muiticenter study on 112 
patients with persistent atrial fibrillation. Patients must have had an episode of persistent 
atrial fibrillation (> 72 hours) and clinical indication of reversion to sinus rhythm. Two 
groups of patients were compared: Group I (56 patients) was treated with amiodarone 
and Group II (56 patients) was treated with amiodarone + Irbesartan. There were no clin- 
ical or echhocardiographic diferences between both groups. The primary and point was 
the length of time to a first recurrence of atrial fibrillation. 
Results: Pharmacologic conversion occurred in 13 (23%) patients of group I and 16 
(32%) of group II (p<0.O5). Cardioversion (electrical or pharmacological) was effective in 
87.5% of patients of group I and 96.5% of patients of group II (p<0.05). After 2 months of 
follow-up, 17 (30%) of the patients assigned to amiodarona and 6 (14%) of those 
assigned to amiodarone+irbasartan had a recurrence of atrial fibrillation (p<0.01), 
Conclusion: These results indicate for the first time in humans that the blockade of AT1 
receptor with irbesartan may lead to better therapeutic managment of patients with per- 
sistent atrial fibrillation. Pretreatment with an angiotansin II receptor antagonist during 
atdal fibrillation appeared to reduce recurrences, possibly due to a reduction of electrical 
remodeling. 
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829-3 Use of Dofetillde in the Treatment of Recurrent Atr ia l  
Fibrlllctlon: L imi ted  E f f i cacy  With Prior Drug Failures 
Andrea M. Russo, Christa Schorr, Brian Bixby, Henry Hsia, Mauraen Nicholas, David 
Callans, Francis E. Marehlinski, University of Pennsylvania Health System, Philadelphia, 
Pennsylvania. 
Background: Dofetilide (DOF) is a class III antiarrhythmic agent (AA) used to reduce 
recurrences of atrial fibrillation (AF). Because of more recent availability, and regulations 
regarding distribution, it is frequently used after other AA agents. 
Methods: We hypothesized that DOF has limited efficacy for AF following other AA fail- 
ures. Thirty-two patients (pts) with AF were treated with DOF after failing other AA 
agents. Dosing was based on creatinine clearance and adjustments based on QT inter- 
val. 
Results: Mean age was 62 +/- 13 years, LVEF 45 +/- 17%, and 20 were men. Structural 
heart disease was present in 21 pts. Pts underwent a mean of 2.6 (range 1 to 6) prior AA 
trials. All pts have been followed for at least 1 month after discharge. Thirteen pts (41%) 
remained on DOF at last follow-up (67 +/- 89 days). DOF was discontinued after 25 +/- 
37 days (range 2 to 164) in 19 pts. Reasons include inefficacy 14 pts (44%), intolerance 
3 pts (9%), and unacceptable increase in QT 2 pts (6%). No pts developed ventricular 
arrhythmias or syncope, and there were no deaths. A comparison was made of apparent 
drug responders versus those with AF recurrence. 
Conclusions: In response to DOF for AF in pts who failed prior AA therapy: 1) DOF is in 
general well-tolerated; 2) Recurrent AF is common (59%); 3) DOF appears more effec- 
tive in pts with structural heart disease, with AF diagnosed for a shorter pedod of time. 
This suggests a difference in arrhythmic substrate for AF in pts with and without overt 
heart disease, that may explain the response to DOlE 
Effective(13pts) Ineffective(14pts) p-value: 
Age 61 +/- 11 57+/- 15 NS 
% males 92% 50% 0.01 
# prior AA drugs 1.2 3.9 <0.01 
# pdor AA drugs failed 1.6 2.9 0.02 
# Class III failed 23% 57% NS 
LVEF (%) 40 +/- 15% 56 +/- 13% <0.01 
LA size (cm) 4.6 4.1 NS 
% no heart disease 15% 50% 0.02 
History CHF 46% 7% 0.03 
1st diagnosis AF (mths) 18 +/- 24 60 +/- 38 <0.01 
Mean dose (mcg/day) 846 911 NS 
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829-4 Effects of Oral Flecainide and Amiodarone on Atr ia l  
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F ibr i l la t ion 
Andreas Bollmann. Karl-Heinz Binias, Ines Toepffer, Reiko Steinert, Jochen Moiling, 
Sven Reek, Helmuf U. Klein, Christoph Geller, Department of Cardiology, University 
Hospital, Magdeburg, Gerrnan v 
Background: Class Ic and III antiarrhythmic drugs are effective in converting recent 
onset but not persistent atrial fibrillation (AF). The purpose of this study was (1) to inves- 
tigate the influence of both oral flecainide (flec) and amiodarona (amio) on atdal fibrilla- 
tory frequency (f) using spectral analysis of the surface ECG in persistent AF, and (2) to 
correlate f with drug-induced conversion. 
Methods: In 37 pts (23 male, mean age 61 years, LAD 45 ram) with AF lasting longer 24 
hours two minute ECG recordings from an orthogonal lead system were analyzed at 
baseline and after 3 days of antiarrhythmic drug treatment. Flec (n=17, 300 mg loading 
dose, 200 to 300 mg/d) and amio (n=20, 1200 mg/d loading dose) were given empirically 
depending on undedying heart disease prior to external electrical cardioversion. Determi- 
nation of f was performed using a three step algorithm (filtadng, QRST averaging and 
subtraction, discrete Fourier transformation of the fibrillatory baseline). 
Results: At baseline mean f measured 6.4 ± 0.5 Hz (range 5.5 to 7.7). Frequency was 
reduced by antiarrhythmic drugs in all pts by 1.4± 0.8 Hz (range 0.2 to 3.0, p<.001 vs 
baseline) with a greater f decrease following flec (2.2 ± 0.5 Hz) compared to amio (1.0 ± 
0.5 Hz, p<.001). Drug-related cardioversion was observed in 9/17 (53%) flec pts as 
opposed to 1/20 (5%) amio pt (p=.001). Sensitivity and specificity for predicting flec 
response were strongly related to f (AUC=.764 using ROC curve analysis). Maximal 
specificity (87 %) with adequate sensitivity (56 %) was present at a fibrillatory frequency 
> 6 Hz. There were no other predictors for drug-induced cardioversion. 
Conclusions: (1) The antifibdllatory effect of flec and amio may be directly monitored 
using spectral analysis of the surface ECG. (2) AF is likely be converted with an oral flec 
bolus when the atrial fibrillatory frequency is below 6 Hz. 
